EP1945246A4 - Immunogene fragmente von t-zell-rezeptor-konstanten domänen und daraus erhaltene peptide - Google Patents

Immunogene fragmente von t-zell-rezeptor-konstanten domänen und daraus erhaltene peptide

Info

Publication number
EP1945246A4
EP1945246A4 EP06796115A EP06796115A EP1945246A4 EP 1945246 A4 EP1945246 A4 EP 1945246A4 EP 06796115 A EP06796115 A EP 06796115A EP 06796115 A EP06796115 A EP 06796115A EP 1945246 A4 EP1945246 A4 EP 1945246A4
Authority
EP
European Patent Office
Prior art keywords
cell receptor
derived therefrom
constant domains
peptides derived
immunogenic fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06796115A
Other languages
English (en)
French (fr)
Other versions
EP1945246A2 (de
Inventor
Irun R Cohen
Francisco Javier Quintana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1945246A2 publication Critical patent/EP1945246A2/de
Publication of EP1945246A4 publication Critical patent/EP1945246A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Rehabilitation Therapy (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
EP06796115A 2005-09-22 2006-09-21 Immunogene fragmente von t-zell-rezeptor-konstanten domänen und daraus erhaltene peptide Withdrawn EP1945246A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71934205P 2005-09-22 2005-09-22
PCT/IL2006/001112 WO2007034489A2 (en) 2005-09-22 2006-09-21 Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom

Publications (2)

Publication Number Publication Date
EP1945246A2 EP1945246A2 (de) 2008-07-23
EP1945246A4 true EP1945246A4 (de) 2009-03-11

Family

ID=37889254

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06796115A Withdrawn EP1945246A4 (de) 2005-09-22 2006-09-21 Immunogene fragmente von t-zell-rezeptor-konstanten domänen und daraus erhaltene peptide

Country Status (7)

Country Link
US (2) US9078843B2 (de)
EP (1) EP1945246A4 (de)
JP (1) JP2009508517A (de)
CN (1) CN101316610A (de)
AU (1) AU2006293420B2 (de)
CA (1) CA2623391A1 (de)
WO (1) WO2007034489A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2288700T3 (en) 2008-05-09 2017-05-22 Agency Science Tech & Res HBV EPITOP-REACTIVE EXOGEN T-CELL RECEPTOR (TCR) AND APPLICATIONS THEREOF
US8986712B2 (en) 2009-11-29 2015-03-24 Yeda Research And Development Co., Ltd. Peptides derived from HIV-1 gp41 transmembrane domain for t-immunomodulation
US20130273089A1 (en) 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
US8524234B2 (en) 2011-11-03 2013-09-03 Tolera Therapeutics, Inc Antibody for selective inhibition of T-cell responses
EP2831109B1 (de) 2012-03-28 2017-12-06 Gadeta B.V. Kombinatorischer gamma-9-delta-2-t-zellen-rezeptorkettenaustausch
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
RS58627B2 (sr) * 2014-04-01 2022-06-30 Biontech Cell&Gene Therapies Gmbh Klaudin-6-specifični imuno receptori i t-ćelijski epitopi
CA2973642A1 (en) * 2015-01-26 2016-08-04 Rinat Neuroscience Corporation Mab-driven chimeric antigen receptor systems for sorting/depleting engineered immune cells
IL314725A (en) * 2015-10-23 2024-10-01 Eureka Therapeutics Inc ׂ A Delaware Corp Antibody/T-cell receptor chimeric structures and their uses
WO2017212072A1 (en) 2016-06-10 2017-12-14 Umc Utrecht Holding B.V. Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
US11186624B2 (en) * 2016-09-23 2021-11-30 Lion Tcr Pte. Ltd. HBV antigen specific binding molecules and fragments thereof
CN110536898B (zh) * 2017-03-09 2023-09-08 易姆赛斯股份公司 用于治疗糖尿病的肽及方法
SG10201913656TA (en) 2017-04-26 2020-03-30 Eureka Therapeutics Inc Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
EP3684805A4 (de) 2017-09-22 2021-06-09 Wuxi Biologics Ireland Limited. Neue bispezifische polypeptidkomplexe
US11365254B2 (en) 2017-09-22 2022-06-21 WuXi Biologics Ireland Limited Bispecific CD3/CD19 polypeptide complexes
EP3903884A4 (de) * 2018-12-26 2023-01-25 Kirin Holdings Kabushiki Kaisha Modifizierter tcr und herstellungsverfahren dafür
WO2023245050A2 (en) * 2022-06-14 2023-12-21 The Regents Of The University Of California Mutated t cell receptor beta chain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016462A1 (en) * 1993-12-13 1995-06-22 La Jolla Institute For Allergy And Immunology Method for antigen-specific immunoregulation by t-cell alpha chain
US5985552A (en) * 1989-03-21 1999-11-16 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
WO2005084137A2 (en) * 2004-03-08 2005-09-15 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Cd25 dna vaccines for treating and preventing t-cell mediated diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4168308A (en) * 1976-03-12 1979-09-18 Apoteksvarucentralen Vitrum Ab Composition for enhancing the administration of pharmacologically active agents
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
JP3875730B2 (ja) 1993-02-22 2007-01-31 サノフィ・アベンティス株式会社 自己免疫疾患の予防治療剤
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
JPH0827018A (ja) * 1994-07-22 1996-01-30 Sanwa Kagaku Kenkyusho Co Ltd 生理活性ペプチド又は蛋白質を含有する薬剤組成物
IL114458A0 (en) 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases
WO1997043411A1 (fr) * 1996-05-10 1997-11-20 Kirin Beer Kabushiki Kaisha Peptides a regions constantes de chaine alpha de recepteur des cellules t, leurs procedes de production et leur utilisation
JPH11302299A (ja) * 1998-04-21 1999-11-02 Kirin Brewery Co Ltd Ｔ細胞リセプターβ鎖定常領域ペプチド、該ペプチドの製造方法及び用途
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
WO2000027870A1 (en) 1998-11-05 2000-05-18 Hadasit Medical Research Services & Development Ltd. Novel amino acid sequences, dna encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof
US6420346B1 (en) 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
EP2301566B1 (de) 2002-05-21 2013-07-03 Irun R. Cohen DNA-Vakzinen, die für Hitzeschockprotein kodieren
US20050260770A1 (en) * 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985552A (en) * 1989-03-21 1999-11-16 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
WO1995016462A1 (en) * 1993-12-13 1995-06-22 La Jolla Institute For Allergy And Immunology Method for antigen-specific immunoregulation by t-cell alpha chain
WO2005084137A2 (en) * 2004-03-08 2005-09-15 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Cd25 dna vaccines for treating and preventing t-cell mediated diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MIMRAN AVISHAI ET AL: "Regulatory T cells in autoimmune diseases: Anti-ergotypic T cells", INTERNATIONAL REVIEWS OF IMMUNOLOGY, HARWOOD ACADEMIC PUBLISHERS, LONDON, GB, vol. 24, no. 3-4, 1 May 2005 (2005-05-01), pages 159 - 179, XP009107107, ISSN: 0883-0185 *
POSNETT D N ET AL: "A NOVEL METHOD FOR PRODUCING ANTI-PEPTIDE ANTIBODIES", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC, US, vol. 263, no. 4, 5 February 1988 (1988-02-05), pages 1719 - 1725, XP002070408, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
US20090035359A1 (en) 2009-02-05
US20150313977A1 (en) 2015-11-05
AU2006293420A1 (en) 2007-03-29
CN101316610A (zh) 2008-12-03
US9078843B2 (en) 2015-07-14
JP2009508517A (ja) 2009-03-05
CA2623391A1 (en) 2007-03-29
AU2006293420B2 (en) 2011-06-30
EP1945246A2 (de) 2008-07-23
WO2007034489A3 (en) 2007-12-06
WO2007034489A2 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
EP1945246A4 (de) Immunogene fragmente von t-zell-rezeptor-konstanten domänen und daraus erhaltene peptide
IL261346A (en) Tissue protective peptides and their uses
IL197094A0 (en) Immunogenic pcpa polypeptides and uses thereof
EP2010572A4 (de) Hpv-polypeptide und das immunsystem stärkende peptide enthaltende zusammensetzungen zur behandlung und prävention von gebärmutterhalskrebs
EP2068898A4 (de) Knochenzement und anwendungsverfahren dafür
EP1937298A4 (de) Verwendung von lactoferrin-fragmenten und hydrolysaten
EP2010209A4 (de) Immunogene wt-1-peptide und verfahren zu ihrer verwendung
EP1722808A4 (de) Egf-rezeptor-epitod-peptide und ihre verwendungen
ZA200901328B (en) Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
EP2170363A4 (de) Gewebespezifische peptid-konjugate und verfahren
IL190885A0 (en) Immunogenic compositions and methods of use
EP2061487A4 (de) Modifizierte cupredoxin-derivierte peptide und verfahren zu ihrer verwendung
IL204743A0 (en) Inhibition of macrophage - stimulating protein receptor (ron) and methods of treatment thereof
EP2061800A4 (de) Zusammensetzungen mit hmw-maa und fragmenten davon sowie verfahren zu ihrer verwendung
EP1890720A4 (de) Pharmazeutische zusammensetzungen mit von casein stammenden peptiden und anwendungsverfahren dafür
ZA201001260B (en) Immunogenic polypeptides and monoclonal antibodies
ZA200702938B (en) Peptides and APL-type derivatives of Hsp60 and pharmaceutical compositions
EP1893233A4 (de) Therapeutische peptide und impfstoffe
EP1940446A4 (de) Nogo-rezeptor-polypeptide und polypeptid-fragmente und ihre verwendungen
ZA200700178B (en) Pharmaceutical composition containing polypeptide fragments of serralysins
ZA200707970B (en) Compositions of HSP60 peptides and viral antigens for vaccination and diagnosis
IL190312A0 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
EP1878745A4 (de) Humanin-rezeptor oder rezeptor für ein humaninähnliches polypeptid
EP1896500A4 (de) Gliomedin, fragmente davon und verfahren zu ihrer anwendung
ZA200800566B (en) Therapeutic peptides and vaccines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080421

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20090209

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/04 20060101ALI20090203BHEP

Ipc: A61K 39/00 20060101AFI20080527BHEP

Ipc: A61K 31/713 20060101ALI20090203BHEP

17Q First examination report despatched

Effective date: 20090624

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130221